Chemically-Induced Disorders, Methamphetamine Use Disorder, Stimulant-Use Disorder, Substance-Related Disorders, Substance Use Disorders
Conditions
Keywords
methamphetamine, psilocybin, psychedelics, stimulants, substance use
Brief summary
The purpose of this research study is to investigate the safety and feasibility of two (2) oral doses of psilocybin when combined with behavioral support for methamphetamine use disorder (MUD). Participants have a diagnosis of methamphetamine use disorder (MUD). Participants can expect to be actively engaged in the study for up to 26 weeks.
Detailed description
The objective of this study is to determine the safety of psilocybin in adult participants with MUD. Eligible participants will be adults with methamphetamine use disorder recruited from the community. After physical and psychological screening, and at least 6 hours of psychological support for the psilocybin dosing, each participant will ingest 1 oral dose of psilocybin. All dosing sessions will be attended by 2 specially trained facilitators, in a dedicated Session Room at the University of Wisconsin School of Pharmacy. After eight hours of observation in the dosing room, the participant will stay overnight in the hospital Clinical Research Unit, and complete an integration session with at least one of the session facilitators before discharge to home. Approximately 4 weeks after the first dose, the participant will receive a second oral dose of psilocybin, with the same length of observation. Participants who decide not to proceed to the second dose will complete two additional integration sessions and study measures through the two-month follow-up. If you are interested in participating in this study, please fill out a brief 1-minute survey at the link in the "More Information" section at the bottom of this record.
Interventions
DRUGPsilocybin
25mg orally followed by 25 mg or 50 mg orally
Sponsors
University of Wisconsin, Madison
Revive Therapeutics, Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
25 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of methamphetamine use disorder
Exclusion criteria
* Positive urine pregnancy at any time point during screening or study participation * Inadequately treated hypertension, defined as 2 blood pressure readings, 10 minutes apart, of greater than 140/90 mmHg systolic/diastolic * Current acute coronary syndrome or angina * History of heart transplant or stroke * Current use of and inability or unwillingness to taper off of medications that may interact with psilocybin * Current insulin dependence, due to Type I or Type II diabetes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of serious adverse events associated with oral psilocybin | Up to 26 weeks | Incidence of serious adverse events attributable to psilocybin as categorized according to NCI Common Toxicity Criteria version 4.0. and assigned attribution (probably, possibly, and not related). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants who complete at least one dose of psilocybin | Up to 26 weeks | Study protocol retention and adherence for preparation, dosing and follow-up visits determined by adherence and retention rates, number of visits attended throughout the duration of the study. |
| Number of participants who complete two-month follow-up visit | Up to 26 weeks | Study protocol adherence for preparation, dosing and follow-up visits determined by adherence and retention rates, number of visits attended throughout the duration of the study. |
| Changes in substance use | Up to 26 weeks | Frequency of use of methamphetamine and other substances will be evaluated and tracked based on participant self-reported use at each visit. |
| Functional changes in psychedelic and addiction-related neurocircuitry using functional magnetic resonance imaging. | Up to 26 weeks | Changes in functional connectivity (FC). Participants will undergo a 15-minute resting-state fMRI scanning sequence to measure changes in FC at rest pre- and post-dose. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORChristopher Nicholas, PhD
University of Wisconsin, Madison
Outcome results
None listed